| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6190165 | Bulletin du Cancer | 2015 | 8 Pages |
Abstract
Therapeutic arsenal in prostate cancer widens for several years. New hormonal therapies such as acetate abiraterone or enzalutamide were the first molecules to revolutionize the treatment of metastatic castration resistant prostate cancer. Several other treatments are on trial targeting different pathways: androgene pathway (TAK-007, ARN-509, ODM-201, TOK-001), immune system (sipuleucel, ipilimumab, PROSTVAC-V/F, tasquinimod), but also tumor cell (PARP inhibitor, cabozantinib). The treatment sequencing will therefore soon be problematic, raising the necessity to identify predictive markers of response to the new therapies.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Constance Thibault, Christophe Massard,